Acurian, Inc. Announces Its Contribution of Over 600 Randomized Patients in Global, Phase III Diabetes Trial at Therapeutic Conference in Amsterdam

Published: Jan 27, 2011

AMSTERDAM--(BUSINESS WIRE)--Acurian, Inc., a leading, full-service provider of patient recruitment and retention solutions, announced today at the Patient Recruitment & Retention for Diabetes & Obesity Studies Conference in Amsterdam that it recently completed its enrollment contribution of over 600 diabetes patients for a global, nine-protocol diabetes study.

Back to news